NUVASIVE, INC. (NASDAQ:NUVA) Files An 8-K Other Events
Item 8.01Other Events.

From November 11 through November 28, 2016, in privately-negotiated transactions, NuVasive, Inc. (the “Company”) repurchased approximately $49.6 million in aggregate principal amount of its 2.75% Convertible Senior Notes due 2017 (the “2017 Notes”) for total consideration of $76.1 million in cash, including accrued interest. Following these repurchases, 2017 Notes representing $76.1 million in principal amount remained outstanding.  In connection with the issuance of the 2017 Notes in June 2011, the Company entered into convertible note hedge transactions and warrant transactions with the initial purchasers (and/or their affiliates) of the 2017 Notes.  The Company intends to modify the convertible note hedge and warrant positions associated with the 2017 Notes to reflect the remaining balance of 2017 Notes outstanding.  

The Company funded the repurchases of the 2017 Notes using available cash, and as November 28, 2016, had no borrowings under its $150 million revolving senior credit facility.  The Company may make additional repurchases of the 2017 Notes in the future and may continue to modify the associated hedge and warrant positions in connection with any repurchases.  Unless earlier converted or repurchased, the 2017 Notes will mature on July 1, 2017.

About NUVASIVE, INC. (NASDAQ:NUVA)

Nuvasive, Inc. is a medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. The Company offers two product lines: spine surgery products and biologics. The Company’s spine surgery products line offerings include thoracolumbar product offerings, cervical product offerings, Intra-Operative Monitoring (IOM) services and disposables, which are used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The Company’s biologics product line offerings includes allograft (donated human tissue), FormaGraft (a collagen synthetic product), Osteocel Plus and Osteocel Pro (each an allograft cellular matrix containing viable mesenchymal stem cells (MSCs)), and AttraX (a synthetic bone graft material), all of which are used to aid the spinal fusion or bone healing process.

NUVASIVE, INC. (NASDAQ:NUVA) Recent Trading Information

NUVASIVE, INC. (NASDAQ:NUVA) closed its last trading session up +0.17 at 64.07 with 1,162,180 shares trading hands.